Literature DB >> 3291388

Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein.

J J Esposito1, J C Knight, J H Shaddock, F J Novembre, G M Baer.   

Abstract

Two infectious raccoon poxvirus (RCN) recombinants for expressing rabies virus surface spike glycoprotein (G) were produced by homologous recombination between raccoon poxvirus DNA and chimeric plasmids previously used for production of vaccinia virus recombinants. Expression of G protein was controlled by vaccinia virus promoter P7.5 (early/late class) or by P11 (late class). Immunoprecipitation of infected cell extracts indicated that both of the RCN recombinants directed faithful expression of G protein. Raccoons that were fed polyurethane baits loaded with either recombinant quickly developed high levels of rabies virus neutralizing antibodies and were protected when challenged with lethal raccoon rabies street virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3291388     DOI: 10.1016/0042-6822(88)90692-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection.

Authors:  D L Lodmell; J W Sumner; J J Esposito; W J Bellini; L C Ewalt
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors:  Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

Review 3.  Non-replicating expression vectors: applications in vaccine development and gene therapy.

Authors:  K J Limbach; E Paoletti
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

Review 4.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Sickness and recovery of dogs challenged with a street rabies virus after vaccination with a vaccinia virus recombinant expressing rabies virus N protein.

Authors:  M Fekadu; J W Sumner; J H Shaddock; D W Sanderlin; G M Baer
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

Review 6.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

7.  Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine.

Authors:  Jordan S Mencher; Susan R Smith; Tim D Powell; Dan T Stinchcomb; Jorge E Osorio; Tonie E Rocke
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  PCR strategy for identification and differentiation of small pox and other orthopoxviruses.

Authors:  S L Ropp; Q Jin; J C Knight; R F Massung; J J Esposito
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

9.  Characterization of rabies glycoprotein expressed in yeast.

Authors:  S R Klepfer; C Debouck; J Uffelman; P Jacobs; A Bollen; E V Jones
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro.

Authors:  D L Lodmell; J J Esposito; L C Ewalt
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.